Norihiko Kamioka, Yoshimitsu Soga, Hideaki Aihara, Yusuke Tomoi, Naotaka Murata, Seiichi Hiramori, Yohei KobayashiKokura Memorial Hospital, Kitakyushu-city, Japan.
The aim of this study was to investigate the outcome following endovascular therapy (EVT) for femoropopliteal (FP) lesion classified into Trans-Atlantic Inter-Society Consensus (TASC) II Class A and B.
METHODS: This study was a multicenter retrospective analysis. A total of 2,742 consecutive patients (3,471 limbs) with FP disease and 2003 limbs with TASCII Class A and B lesions were analyzed in current study; 1169 (58.4%) were stenting, 834 (41.6%) were plain old balloon angioplasty (POBA) alone.
RESULTS: The mean follow-up term were 4.6±0.1 years. The mean reference vessel diameter(RVD) was 58.7±33.8 mm and the mean lesion length was 5.2±1.0mm. Primary patency was significantly higher in the stent group (85.3%, 69.6% and 59.9% at 1, 3 and 5 years) than that in the POBA group (76.2%, 59.6% and 49.3% at 1, 3 and 5 years; p<0.0001). Assisted primary patency was also better in the stent group than that in the POBA group (p=0.0002) and the difference in secondary patency between in the two groups was similarly significant (p=0.006). Limited to lesions with RVD below 4.5mm, there was no difference in primary patency between in the two groups (stent vs POBA; 73.0% vs. 74.8%, 57.2% vs. 53.2% and 46.8% vs. 45.4% at 1, 3 and 5 years, p=0.67). Diabetes, hemodialysis, the history of cerebrovascular disease, absence of cilostazol, POBA alone and RVD <4.5mm were found to be independent predictors of primary patency.
CONCLUSIONS: FP stenting improves the primary, assisted-primary and secondary patency for the femoropopliteal TASCII Class A and B lesions.
AUTHOR DISCLOSURES: H. Aihara: Nothing to disclose; S. Hiramori: Nothing to disclose; N. Kamioka: Nothing to disclose; Y. Kobayashi: Nothing to disclose; N. Murata: Nothing to disclose; Y. Soga: Nothing to disclose; Y. Tomoi: Nothing to disclose.
Posted April 2013